

CLINICAL LEADERSHIP EXECUTIVE OUTBRIEF	
Date of meeting	22nd September 2020
Attendees	Group Triumvirates (Group Directors, Group Directors of Nursing and Group Directors of Operations), Director of Therapies and Executive Directors.
Apologies	Toby Lewis, Kam Dhami, Liam Kennedy, Rachel Barlow
Key points of discussion relevant to the Board	<ul style="list-style-type: none"> • Interim governance arrangements confirmed with the CLE for clarity on whom to escalate concerns to • Discussion had on winter planning with some modification and clarification proposed • Presentation on ACP posts and potential role in care provision in MMUH, supporting traditional clinical roles, particularly in the acute environment
Positive highlights of note	<ul style="list-style-type: none"> • Support for ACP model but further review of work force options needed to consider broad requirements for MMUH • All 52 week waits have had a harm review undertaken
Matters of concern or key risks to escalate to the Board	<ul style="list-style-type: none"> • None •
Matters presented for information or noting	<ul style="list-style-type: none"> • IQPR • Chief Executive's report to the September Trust Board
Decisions made	<ul style="list-style-type: none"> • Review winter plan with medicine to make sure bed changes proposed are deliverable

David Carruthers, Acting Chief Executive
Acting Chair of the Clinical Leadership Executive
For the meeting of the Trust Board scheduled for 1st October 2020